Search clinical trials for: intermediate AMD

Total 1945 results

Providence Health & Services

Available

Intermediate-size IND for Treatment of KRAS G12V-mutant Tumors

KRAS G12V Mutant Advanced Epithelial Cancers
National Eye Institute (NEI)

Completed

Intestinal Bacteria and Ocular Inflammatory Disease

Uveitis

United States
Janssen Research & Development, LLC

Active, not recruiting

A Study of JNJ-64619178, an Inhibitor of PRMT5 in Participants With Advanced Solid Tumors, NHL, and Lower Risk MDS

Neoplasms | Myelodysplastic Syndromes | Non-Hodgkin Lymphoma | Solid Tumor, Adult

United States, Spain, Israel, Germany, Canada
Novartis Pharmaceuticals

Completed

Multiple Dose Safety and Efficacy of LKA651 in Patients With Diabetic Macular Edema

Diabetic Macular Edema

Germany, Turkey, United States, Spain, Puerto Rico
Janssen Research & Development, LLC
Janssen Research & Development, LLC

Active, not recruiting

Follow-up Gene Therapy Trial for the Treatment of X-linked Retinitis Pigmentosa Associated With Variants in the RPGR Gene

X-Linked Retinitis Pigmentosa

United States, Canada, Israel, United Kingdom, Denmark, France, Belgium, Italy, Netherlands, Switzerland, Spain
AbbVie
AbbVie

Enrolling by invitation

Long-Term Follow-Up Study of RGX-314 Administered in the Suprachoroidal Space for Participants With nAMD

Gene Therapy | AMD | nAMD | Wet AMD | Neovascular Age-Related Macular Degeneration (nAMD) | wAMD

United States
Novartis Pharmaceuticals

Completed

A Non-interventional Study to Assess the Influence of Automated Optical Coherence Tomography Image Enrichment With Segmentation Information on Disease Activity Assessment in Patients Treated With Licensed Anti- VEGF Injections (RAZORBILL)

Neovascular Age-Related Macular Degeneration

Spain, Italy, Germany, Canada, Ireland
UNICANCER
Ipsen

Active, not recruiting

Triptorelin and Radiation Therapy in Treating Patients Who Have Undergone Surgery for Intermediate-Risk Stage III or Stage IV Prostate Cancer

Prostate Cancer

France
AbbVie
AbbVie

Enrolling by invitation

Long-term Follow-Up Study of RGX-314 and Fellow Eye Substudy (RGX-314 SRLTFU)

Wet Macular Degeneration | Neovascular Age-related Macular Degeneration

United States
National Eye Institute (NEI)

Active, not recruiting

Study of Dark Adaptation in Age-Related Macular Degeneration

Age-Related Macular Degeneration

United States
H. Lee Moffitt Cancer Center and Research Institute

Active, not recruiting

Validation Study on the Impact of Decipher® Testing - VANDAAM Study (VANDAAM)

Prostate Cancer

United States
Sidney Kimmel Comprehensive Cancer Center at Johns...
MacroGenics

Active, not recruiting

Neoadjuvant Enoblituzumab (MGA271) in Men With Localized Intermediate and High-Risk Prostate Cancer

Prostate Cancer

United States
National Eye Institute (NEI)

Completed

AMD Ryan Initiative Study (ARIS)

Age-Related Macular Degeneration

United States
Rigshospitalet, Denmark
University Hospital Bispebjerg and Frederiksberg; Hillerod Hospital, Denmark; Herlev and Gentofte Hospital and other collaborators

Active, not recruiting

Low Dose Thrombolysis, Ultrasound Assisted Thrombolysis or Heparin for Intermediate High Risk Pulmonary Embolism (STRATIFY)

Pulmonary Embolism

Denmark
Jesper Kjaergaard
Zealand University Hospital; Copenhagen University Hospital at Herlev

Active, not recruiting

Percutaneous Embolectomy, Ultrasound Assisted Thrombolysis or Heparin for Intermediate High Risk Pulmonary Embolism (STRATIFY-II)

Pulmonary Embolism

Denmark
Albert Einstein College of Medicine

Active, not recruiting

A Pilot Study of Ultra-High-Dose Hypofractionated or Single-Dose Radiotherapy for Intermediate Risk Prostate Cancer (PROSINT)

Prostate Cancer

United States
[Redacted]

Withheld

[Trial of device that is not approved or cleared by the U.S. FDA]
Boehringer Ingelheim

Completed

A Study to Test How Well Different Doses of BI 771716 Are Tolerated by People With an Advanced Form of Age-related Macular Degeneration (AMD) Called Geographic Atrophy

Geographic Atrophy

United States
Abramson Cancer Center at Penn Medicine

Active, not recruiting

Mild Hypofractionation With Proton Therapy or Intensity Modulated Radiation Therapy (IMRT) for Intermediate-Risk Prostate Cancer

Prostate Adenocarcinoma

United States
UroGen Pharma Ltd.

Terminated

A Phase 3 Study of UGN-102 for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (ATLAS)

Bladder Cancer | Urothelial Carcinoma Bladder | Urothelial Carcinoma

United States, Israel, Russian Federation, Georgia, Bulgaria, Estonia, Latvia, Poland, Serbia, Ukraine
Alexion Pharmaceuticals, Inc.

Active, not recruiting

A Study of Danicopan in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration

Geographic Atrophy

United States, France, Germany, Italy, Spain, Korea, Republic of, United Kingdom, Canada, Japan, Czechia, Australia, Latvia, Hungary, Slovakia
Sorlandet Hospital HF

Completed

Mechanisms of Retinal Revascularization and Clinical Indicators of Neovascular AMD Relapse

Wet Macular Degeneration

Norway
Novartis Pharmaceuticals

Completed

A Study to Assess the Effects of Brolucizumab in Adult Patients With Neovascular Age Related Macular Degeneration (OCTOPUS)

Neovascular Age Related Macular Degeneration

France
ACELYRIN Inc.

Active, not recruiting

Phase 2b Pivotal Study of Izokibep in Non-infectious, Intermediate-, Posterior- or Pan-uveitis

Uveitis

United States, Austria, Czechia, France, Germany, Italy, Spain
St. Jude Children's Research Hospital
Novartis Pharmaceuticals

Completed

SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors

Glioma | Neoplasms | Glioblastoma | Neoplasms, Neuroepithelial | Central Nervous System Neoplasms | Brain Cancer | Brain Tumor | Ependymoma | Medulloblastoma | Anaplastic Astrocytoma | Anaplastic Ganglioglioma | Anaplastic Ependymoma | Anaplastic Oligodendroglioma | Pineoblastoma | Recurrent Medulloblastoma | CNS Tumor | Pediatric... and other conditions

United States
National Eye Institute (NEI)

Active, not recruiting

Vitamin A Palmitate Supplementation in People With Age-Related Macular Degeneration (and Without Reticular Pseudodrusen) and Delayed Dark Adaptation

AMD

United States
Novartis Pharmaceuticals

Completed

An Extension Study Assessing the Efficacy and Safety of Brolucizumab in a Treat-to-Control Regimen in Patients With Neovascular Age-related Macular Degeneration Who Have Completed the CRTH258A2303 (TALON) Study (TALON Ext)

Neovascular Age-related Macular Degeneration

United States, Czechia, Italy, Taiwan, Australia, Israel, Belgium, France, Spain, Germany, Korea, Republic of, Portugal, Sweden, Netherlands, Malaysia, Switzerland
Asociación para Evitar la Ceguera en México

Withdrawn

A Phase I/IIa Study for the Treatment of Uveitis With Iontophoresis

Uveitis

Mexico
Alvotech Swiss AG

Active, not recruiting

Clinical Study to Compare Efficacy and Safety of AVT06 and EU-Eylea (ALVOEYE) (ALVOEYE)

Neovascular (Wet) AMD

Slovakia, Czechia, Georgia, Japan, Latvia
Paul S. Bernstein

Active, not recruiting

The Moran AMD Genetic Testing Assessment Study (MAGENTA)

Age-Related Macular Degeneration | Genetic Testing | Nutritional Biomarkers

United States
Karyopharm Therapeutics Inc

Active, not recruiting

Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants With Relapsed/Refractory Cancer Indications

Acute Myeloid Leukemia (AML) | Metastatic Colorectal Cancer (mCRC) | Metastatic Castration-Resistant Prostate Cancer (mCRPC) | Relapsed/Refractory Multiple Myeloma (RRMM) | Higher-Risk Myelodysplastic Syndrome (HR-MDS) | Newly Diagnosed Intermediate/High-Risk MDS

United States, France, Canada, Spain, China
University of Chicago

Active, not recruiting

Feasibility of Hormones and Radiation for Intermediate or High Risk Prostate Cancer

Prostate Cancer

United States
Clene Nanomedicine

Available

Intermediate Expanded Access Protocol (EAP) CNMAu8.EAP02

Amyotrophic Lateral Sclerosis

United States
Clene Nanomedicine
National Institute of Neurological Disorders and Stroke (NINDS)

Available

Intermediate Expanded Access Protocol CNMAu8.EAP04

Amyotrophic Lateral Sclerosis | ALS | PALS
Meddoc
Oslo University Hospital

Completed

Validation of Bulbicam for DR- and AMD-patients

Age-Related Macular Degeneration | Diabetic Retinopathy

Norway
Fudan University

Completed

cTACE Plus Sintilimab for Unresectable Intermediate-stage HCC With Beyond Up-to-seven Criteria

Hepatocellular Carcinoma

China
Clene Nanomedicine
Massachusetts General Hospital

Available

Intermediate Expanded Access Protocol for ALS

Amyotrophic Lateral Sclerosis

United States
University of Chicago
Janssen, LP

Suspended

Focal Prostate Ablation With Androgen Deprivation and Novel Hormonal Therapy for Intermediate Risk Prostate Cancer

Prostate Cancer

United States
Novartis Pharmaceuticals

Active, not recruiting

Observational Study to Evaluate Fluid Resolution and Effectiveness in Patients Receiving Beovu in Neovascular Age-related Macular Degeneration and Visual Impairment Due to Diabetic Macular Edema (BLUE SKY)

Diabetic Macular Edema (DME) | Neovascular Age-related Macular Degeneration (nAMD)

Germany
Fred Hutchinson Cancer Center
National Heart, Lung, and Blood Institute (NHLBI); Rocket Pharma Limited

Terminated

Gene Therapy for Fanconi Anemia

Fanconi Anemia

United States
Novartis Pharmaceuticals

Completed

Study to Assess the Efficacy and Safety of Brolucizumab 6mg Compared to Aflibercept 2 mg in a Treat-to-control Regimen (TALON) (TALON)

Age-related Macular Degeneration

United States, Austria, Czechia, Italy, Taiwan, Belgium, Germany, Australia, Israel, Canada, France, Spain, Korea, Republic of, United Kingdom, Portugal, Netherlands, Sweden, Argentina, Malaysia, Switzerland
University of Leipzig
Curis, Inc.

Terminated

Treatment of Anemia in Patients With Very Low, Low or Intermediate Risk Myelodysplastic Syndromes With CA-4948 (LUCAS)

Myelodysplastic Syndromes | Anemia

Germany
Memorial Sloan Kettering Cancer Center

Active, not recruiting

A Study of Shorter Course Hormone Therapy and Radiation for High-risk Prostate Cancer

Prostate Cancer

United States
Istanbul Medipol University Hospital

Completed

Examining The Effect of Chronotype Differences on Sleep Quality and Pregnancy Symptoms in Pregnant Women

Pregnancy Complications | Chronotype

Turkey
Ionis Pharmaceuticals, Inc.

Active, not recruiting

GOLDEN STUDY: A Study to Assess Safety and Efficacy of Multiple Doses of IONIS-FB-LRx in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration (AMD)

Macular Degeneration | Geographic Atrophy

United States, Spain, Australia, Austria, Canada, Czechia, Netherlands, New Zealand, Poland
Hoffmann-La Roche

Active, not recruiting

A Study Comparing Alectinib With Crizotinib in Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer Participants (ALEX)

Non-Small Cell Lung Cancer

United States, Korea, Republic of, Canada, Taiwan, Australia, France, Hong Kong, Italy, Portugal, Spain, United Kingdom, Brazil, Poland, Guatemala, Singapore, Thailand, Serbia, Ukraine, Bosnia and Herzegovina, China, Costa Rica, E... and more
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Glutaminase Inhibitor CB-839 and Azacitidine in Treating Patients With Advanced Myelodysplastic Syndrome

Chronic Myelomonocytic Leukemia | Myelodysplastic Syndrome | High Risk Myelodysplastic Syndrome | Acute Myeloid Leukemia With Multilineage Dysplasia | Blasts 20-30 Percent of Bone Marrow Nucleated Cells | Blasts 20-30 Percent of Peripheral Blood White Cells | IPSS Risk Category Intermediate-2

United States
Chimerix

Available

Intermediate-size Expanded Access to ONC201 for Patients With H3 K27M-mutant and/or Midline Gliomas

Glioma | H3 K27M

United States
Gradalis, Inc.

Active, not recruiting

A Trial of Vigil for Participants With Ovarian Cancer (VITAL)

Ovarian Neoplasms | Ovarian Cancer

United States
Bristol-Myers Squibb

Active, not recruiting

A Study to Compare the Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Participants With International Prognostic Scoring System Revised (IPSS-R) Low- or Intermediate-risk Myelodysplastic Syndrome (MDS)

Myelodysplastic Syndromes

Argentina, Canada, France, Germany, Italy, Korea, Republic of, Poland, United States, Australia, China, Czechia, Denmark, Greece, Hong Kong, Japan, Spain, Sweden

Search clinical trials for: intermediate AMD

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Philippines

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations